EI
ABOS icon

Ethic Inc’s Acumen Pharmaceuticals ABOS Stock Holding History

Ethic Inc’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,377
Closed -$12.7K – 1193
2025
Q2 		$12.7K Buy
+11,377
New +$12.2K ﹤0.01% 1208

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Ethic Inc's ABOS Position: Q3 2025 in Review

Ethic Inc sold out of Acumen Pharmaceuticals (ABOS) in Q3 2025, closing a stake of 11,377 shares — an estimated $12.7K sold.

Ethic Inc first reported a position in ABOS in Q2 2025 and held it in 1 quarter. The position peaked at $12.7K in Q2 2025. 69 funds tracked by Wall St. Rank hold ABOS as of Q3 2025.

  • Ethic Inc reported no remaining Acumen Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ethic Inc sold 11,377 Acumen Pharmaceuticals shares in Q3 2025, an estimated $12.7K.
  • Ethic Inc first reported a position in Acumen Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Ethic Inc's Acumen Pharmaceuticals position peaked at $12.7K in Q2 2025.
  • 69 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2025.

Based on Ethic Inc's 13F filing for Q3 2025, filed 17 Oct 2025.